developer_researcher,stage_of_development,product_category,country_name,ioc_country_code,date_last_updated,anticipated_next_steps,funder
AbVision,Pre-clinical,Unknown,United States,USA,5/13/2020,Unknown,Unknown
AdaptVac (PREVENT-nCoV consortium),Phase I/II,Protein subunit,Denmark,DEN,5/14/2021,"Phase I/II (COUGH-1) study began March 2021, initial results expected to be released in July 2021; Pre-clinical data published January 2021",European Commission (Horizon 2020 Program)
Adeleke University,Pre-clinical,Unknown,Nigeria,NGR,6/30/2020,Unknown,Unknown
Adimmune Corporation,Phase I,Protein subunit,Chinese Taipei,TPE,9/2/2020,Phase I began end of August 2020; Phase II expected to begin November 2020,Unknown
"Aivita Biomedical, Inc./ National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",Phase I,Replicating viral vector,Indonesia,INA,1/31/2021,Phase I/II expected to begin February 2021; Phase I began December 2020,Unknown
AJ Vaccines,Pre-clinical,Protein subunit,Denmark,DEN,Prior to 4/20/2020,Unknown,Unknown
"Anhui Zhifei Longcom Biopharmaceutical/ Institute of Microbiology, Chinese Academy of Sciences",Phase III,Protein subunit,China,CHN,4/30/2021,"China and Uzbekistan granted ""emergency use"" approval in March 2021; Phase III began December 2020; Phase I and II safety and immunogenicity data released December 2020; Phase II began July 2020; Received approval to launch clinical trials in China in June 2020",Unknown
Ankara University,Pre-clinical,Non-replicating viral vector,Turkey,TUR,7/9/2020,Unknown,Unknown
AnyGo Technology,Pre-clinical,Protein subunit,China,CHN,5/4/2020,Unknown,Unknown
"Applied Biotechnology Institute, Inc.",Pre-clinical,Protein subunit,United States,USA,5/12/2020,Unknown,Unknown
Arcturus/Duke-NUS/ Catalent,Phase II,RNA-based vaccine,United States,USA,8/3/2021,"Phase IIa of Phase I/II trial began recruiting January 2021; Received approval to proceed with Phase II study in Singapore (December 2020) and the US (January 2021); Phase I/II interim data released December 2020; Pre-clinical results released September and December 2020; Phase I/II began August 2020, initial results expected Q4 2020; Received approval to launch clinical trials in Singapore end of July 2020",Unknown
Arizona State University,Pre-clinical,Virus-like particle,United States,USA,2/12/2021,Unknown,Unknown
Arizona State University,Pre-clinical,Virus-like particle,United States,USA,2/12/2021,Unknown,Unknown
ARTES Biotechnology,Pre-clinical,Virus-like particle,Germany,GER,5/4/2020,Unknown,Unknown
AstraZeneca,Phase II/III,Non-replicating viral vector,Great Britain,GBR,7/29/2021,"Phase II/III dosed end of June 2021, in both previously vaccinated (with two doses of Vaxzevria or an mRNA vaccine) and unvaccinated adults to determine the safety and immunogenicity of AZD2816, a vaccine for the prevention of COVID-19 caused by variant strains of the SARS-CoV-2 virus",Unknown
Aurobindo,Pre-clinical,Replicating viral vector,India,IND,7/15/2020,Unknown,Unknown
Axon Neuroscience SE,Pre-clinical,Protein subunit,Slovakia,SVK,11/16/2020,Pre-clinical results released September 2020,Unknown
Baiya Phytopharm/ Chula Vaccine Research Center,Pre-clinical,Protein subunit,Thailand,THA,6/30/2021,Phase I expected to begin August 2021; Animal trial results announced September 2020,Unknown
Baylor College of Medicine,Pre-clinical,Protein subunit,United States,USA,Prior to 4/20/2020,Unknown,Unknown
Beijing Institute of Biological Products/ Sinopharm,Phase III,Inactivated virus,China,CHN,6/8/2021,"Vietnam granted approval on 6/4/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 5/7/2021; Indonesia granted ""emergency use"" approval on 4/30/2021; Hungary granted ""emergency use"" approval on 1/29/2021; Pakistan granted ""emergency use authorization"" on 1/18/2021; China ""granted conditional market approval"" on 12/31/2020; Midterm clinical results released on 12/30/2020; Bahrain National Health Regulatory Authority (NHRA) ""approved"" on 12/13/2020; UAE Ministry of Health and Prevention (MOHAP) announced ""official registration"" on 12/9/2020, following review of Phase III interim analysis; Phase I/II results published October 2020; Phase III trial began July 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Unknown
Bezmialem Vakif University,Pre-clinical,Virus-like particle,Turkey,TUR,7/21/2020,Unknown,Unknown
Bharat Biotech International Limited,Phase I,Non-replicating viral vector,India,IND,3/28/2021,Phase I began March 2021,Unknown
Bharat Biotech/ Indian Council of Medical Research/ National Institute of Virology/ Ocugen/ Precisa Medicamentos,Phase III,Inactivated virus,India,IND,7/6/2021,"Phase III efficacy analysis results announced on 7/2/2021; Phase III second interim analysis results announced on 4/21/2021; Authorized for ""emergency use"" in Nepal and Zimbabwe as of March 2021; Phase II interim analysis and Phase I follow-up results published 3/8/2021; Phase III interim analysis results announced 3/3/2021; Neutralization of UK-variant with vaccine-elicited sera announced January 2021; India granted ""permission for emergency use"" on 01/03/2021; Phase I and II safety and immunogenicity data released December 2020 and published January 2021; Phase III began November 2020; Phase I/II study: Phase I began July 2020 and Phase II began September 2020, initial results expected September 2020; Animal study results released September 2020",Unknown
Bharat Biotech/ Thomas Jefferson University,Pre-clinical,Non-replicating viral vector,India,IND,2/27/2021,Pre-clinical data published October 2020,Unknown
BiOCAD,Pre-clinical,RNA-based vaccine,Russia,RUS,Prior to 4/20/2020,Animal studies begin in April 2020,Unknown
BiOCAD/ IEM,Pre-clinical,Replicating viral vector,Russia,RUS,Prior to 4/20/2020,Unknown,Unknown
Biological E Ltd/ Dynavax/ Baylor College of Medicine,Phase I/II,Protein subunit,India,IND,4/28/2021,"Phase III clinical trial received approval to start by CDSCO in April 2021; CEPI partnership announced December 2020; Phase I/II began November 2020, interim data expected Q1 2021",Coalition for Epidemic Preparedness Innovations (CEPI)
BiOMVis Srl/ University of Trento,Pre-clinical,Protein subunit,Italy,ITA,5/12/2020,Unknown,Unknown
BioNet Asia/ Technovalia/ Vax4COVID/ The University of Sydney/ The University of Western Australia/ Telethon Kids Institute/ PharmaJet,Phase I,DNA-based,Australia,AUS,7/29/2021,Phase I dosed end of June 2021,Australian Government Medical Research Future Fund (MRFF)
BioNTech/ Pfizer/ Fosun Pharma/ Rentschler Biopharma,Authorized,RNA-based vaccine,Germany,GER,7/29/2021,"U.S. FDA granted Priority Review designation for the Biologics License Application (BLA) on 7/16/2021 and the Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA is in January 2022; Vietnam granted ""emergency use"" approval on 6/12/2021; European Union expanded Conditional Marketing Authorization (CMA) to include individuals 12-15 years of age on 5/28/2021; U.S. FDA expanded Emergency Use Authorization (EUA) to include individuals 12-15 years of age on 5/10/2021; Announced initiation of Biologics License Application (BLA) with the U.S. FDA on 5/7/2021; Phase III updated topline results announced 4/1/2021; Phase III trial in adolescents (12-15 years) topline results announced 3/31/2021; Phase I/II/III continuous study in children 11 years to 6 month old dosed March 2021; Real-world data gathered by the Israel Ministry of Health announced on 3/11/2021; Evaluation of the safety and immunogenicity of a third dose (30 µg booster of the current vaccine) 6 to 12 months after receiving initial two-dose regimen began 2/25/2021; New stability data at standard freezer temperature was submitted to the U.S. FDA as of 2/19/2021; Phase II/III study in healthy pregnant women 18 years of age and older dosed 2/18/2021; Results from in vitro studies on neutralization of variants of SARS-CoV-2 by BNT162b2 vaccine-elicited sera announced January 2021; Phase I (China) preliminary safety and immunogenicity data released January 2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 12/31/2021; Argentina authorized under ""emergency registration"" on 12/22/2020; European Commission granted a ""conditional marketing authorisation"" (CMA) on 12/21/2020, following European Medicines Agency (EMA) recommendation to grant CMA; U.S. FDA issued ""emergency use authorization"" on 12/11/2020; Mexico COFEPRIS granted ""emergency use authorization"" on 12/11/2020; Saudi Food and Drug Authority (SFDA) ""approved the registration"" of the vaccine on 12/10/2020; Health Canada ""authorized"" on 12/9/2020; Bahrain granted ""emergency use authorization"" on 12/4/2020; U.K. MHRA granted ""temporary authorization for emergency use"" on 12/2/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/20/2020; Phase III complete analysis results announced 11/18/2020, interim analysis results announced 11/09/2020; Phase I data published October 2020; FDA approved late-stage trial enrollment of children 12 years and older in October 2020; EMA rolling submission initiated on 10/6/2020; Study protocol for late-stage clinical trials released Sept 2020; Amended protocol to FDA to expand trial enrollment to 44,000 participants; Phase IIb/III trial began Jul 2020; FDA granted Fast Track designation for BNT162b1 and BNT162b2 in Jul 2020; Selected for US Operation Warp Speed in Jul 2020; Phase I/II began Apr 2020; preliminary data released Jul 2020, additional data published Aug, Sept, and Dec 2020; Pre-clinical data released Sept 2020 and Dec 2020",Unknown
Bogazici University,Pre-clinical,Protein subunit,Turkey,TUR,6/30/2021,Clinical trials expected to begin summer 2021,Unknown
CanSino Biologics/ Beijing Institute of Biotechnology/ Petrovax,Phase III,Non-replicating viral vector,Russia,RUS,6/14/2021,"Authorized for ""emergency use"" in Argentina, Chile, Hungary, Pakistan, and Mexico, and for ""conditional approval"" in China as of June 2021; Filed ""conditional marketing authorization"" with China's National Medical Products Administration (NMPA) on 2/24/2021; Phase III dosed September 2020; Phase II began April 2020, initial results released May 2020, mid-phase results released July 2020; China’s Central Military Commission ""approved the use of the vaccine by the military"" in June 2020",Unknown
"CanSino Biologics/ Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",Pre-clinical,Non-replicating viral vector,China,CHN,11/2/2020,Phase I recruitment began end of September 2020,Unknown
CanSino Biologics/Precision Nanosystems,Pre-clinical,RNA-based vaccine,China,CHN,5/21/2020,Unknown,Unknown
"Catholic University/ Millennium Institute of Immunology and Immunotherapy/ Technological Consortium in Clinical Molecular Biomedicine, Chile",Pre-clinical,Unknown,Chile,CHI,4/23/2020,Unknown,Unknown
"Cellid Co., Ltd./IAVI",Phase I/II,Replicating viral vector,South Korea,KOR,3/22/2021,Phase IIa is expected to be dosed in early April 2021; Phase I/IIa trial began December 2020,Unknown
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Phase III,Protein subunit,Cuba,CUB,6/2/2021,"Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began February 2021, Phase I (ABDALA) trial began December 2020",Unknown
"Center for Genetic Engineering and Biotechnology (CIGB), Havana",Phase I/II,Protein subunit,Cuba,CUB,1/31/2021,Phase I of Phase I/II (MAMBISA) trial began December 2020,Unknown
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Pre-clinical,Non-replicating viral vector,Spain,ESP,Prior to 4/20/2020,Unknown,Unknown
"Centro Nacional Biotecnologia (CNB-CSIC), Spain",Pre-clinical,RNA-based vaccine,Spain,ESP,Prior to 4/20/2020,Unknown,Unknown
Chimeron Bio/ George Mason University's National Center for Biodefense and Infectious  Disease,Pre-clinical,RNA-based vaccine,United States,USA,6/17/2020,Unknown,Unknown
China CDC / Tongji University / Stermina,Pre-clinical,RNA-based vaccine,China,CHN,Prior to 4/20/2020,Unknown,Unknown
Chula Vaccine Research Center,Pre-clinical,DNA-based,Thailand,THA,9/23/2020,Unknown,Unknown
Chulalongkorn University/ Chula Vaccine Research Center/University of Pennsylvania,Phase I,RNA-based vaccine,Thailand,THA,7/29/2021,Phase II expected to begin August 2021; Phase I began June 2021,Unknown
"Chulalongkorn University/ GPO, Thailand",Pre-clinical,Protein subunit,Thailand,THA,6/1/2020,Unknown,Unknown
Chumakov Federal Scientific Center for Research and Development of Immune and Biological Products of the Russian Academy of Sciences,Phase III,Inactivated virus,United States,USA,6/8/2021,"Phase III began March 2021; Russia ""registered"" the vaccine in February 2021; Clinical trials began Ocotober 2020",Unknown
City of Hope Medical Center,Phase I,Non-replicating viral vector,United States,USA,8/3/2021,Phase II expected to begin August 2021; Phase I dosed December 2020,Unknown
Clover Biopharmaceuticals Inc./ Dynavax,Phase II/III,Protein subunit,India,IND,7/6/2021,"Phase II/III (SPECTRA) trial with Dynavax adjuvant dosed March 2021, fully enrolled as of July 2021; Clover and GSK discontinued their partnership as of February 2021; Phase I safety and immunogenicity data released December 2020 and published January 2021; Phase II/III trial with Dynavax adjuvant expected to begin during first half of 2021; Phase II/III trial with GSK adjuvant is not expected to move forward; Pre-clinical results released September 2020; CEPI partnership expanded in July and November 2020, Phase I trial began June 2020, preliminary results expected in the near future",Coalition for Epidemic Preparedness (CEPI)
Codagenix / Serum Institute of India,Phase I,Live attenuated virus,United States,USA,7/19/2021,"Pre-clinical research published June 2021; Phase I trial dosed January 2021, initial data expected by mid-2021; Phase I recruitment began December 2020",Unknown
Codiak BioSciences/ Ragon Institute,Pre-clinical,Unknown,United States,USA,6/4/2020,Unknown,Unknown
CureVac/Bayer/Novartis,Phase III,RNA-based vaccine,Germany,GER,7/6/2021,"Phase IIb/III final analysis results released 6/30/2021; Phase IIb/III second interim analysis results released 6/16/2021; Initiated rolling submission with Swissmedic on 4/19/2021; Initiated rolling submission with European Medicines Agency (EMA) on 2/12/2021; Phase III trial began December 2020; Phase IIb/III (HERALD) trial began recruiting December 2020; Phase IIa trial began end of September 2020; Phase I trial began June 2020, interim results reported November 2020; Pre-clinical data released October 2020",Coalition for Epidemic Preparedness (CEPI); European Commission; Gates Foundation; Defense Advanced Research Projects Agency (DARPA); German Government; European Investment Bank (EIB); German Federal Ministry of Education and Research (BMBF)
CureVac/UK Government (Vaccines Taskforce),Pre-clinical,RNA-based vaccine,Germany,GER,2/5/2021,Collaboration to develop and manufacture variant vaccines for commercial supply and distribution in the UK and its territories was entered in February 2021,Unknown
Daiichi-Sankyo/ University of Tokyo's Institute of Medical Science,Phase I/II,RNA-based vaccine,Japan,JAP,3/22/2021,Phase I/II clinical trial began March 2021,Unknown
Doherty Institute,Pre-clinical,Virus-like particle,Australia,AUS,7/8/2020,Unknown,Unknown
DZIF - German Center for Infection Research/ CanVirex AG,Pre-clinical,Replicating viral vector,Germany,GER,6/30/2020,Unknown,Unknown
Ege University Drug Development and Pharmacokinetic Research Application Center (ARGEFAR)/ Scientific and Technological Research Council of Turkey (TUBITAK),Pre-clinical,DNA-based,Turkey,TUR,9/23/2020,Unknown,Unknown
Elixirgen Therapeutics/ Fujita Health University,Phase I/II,RNA-based vaccine,United States,USA,5/25/2021,Phase I/II began at Fujita Health University Hospital in May 2021,Japan Agency for Medical Research and Development (AMED)
Emergex Vaccines/ George Mason University's National Center for Biodefense and Infectious Diseases (NCBID),Pre-clinical,Unknown,United States,USA,4/24/2020,Unknown,Unknown
Entos Pharmaceuticals/ Cytiva,Phase I/II,DNA-based,Canada,CAN,5/31/2021,Phase I/II began April 2021,Canadian Institutes of Health Research (CIHR)/ Research Nova Scotia (RNS)/ Institute for Ageing (IA)/ National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
EpiVax,Pre-clinical,Protein subunit,United States,USA,5/27/2020,Unknown,Unknown
EpiVax / University of Georgia,Pre-clinical,Protein subunit,United States,USA,Prior to 4/20/2020,Unknown,Unknown
Erciyes University,Phase III,Inactivated virus,Turkey,TUR,6/30/2021,"Phase III began June 2021; Phase II dosed February 2021; Phase I began November 2020, completed on December 14, 2020",Unknown
Erciyes University,Pre-clinical,Non-replicating viral vector,Turkey,TUR,8/3/2020,Unknown,Unknown
eTheRNA Immunotherapies / EpiVax/ Nexelis/ REPROCELL / Centre for the Evaluation of Vaccination of the University of Antwerp,Pre-clinical,RNA-based vaccine,Belgium,BEL,5/4/2020,Start Phase I early 2021,Unknown
ExpreS2ion,Pre-clinical,Protein subunit,Sweden,SWE,Prior to 4/20/2020,Unknown,Unknown
Farmacológicos Veterinarios SAC (FARVET SAC),Pre-clinical,Replicating viral vector,Peru,PER,6/30/2021,Pre-clinical results released March 2021,Unknown
Farmacológicos Veterinarios SAC (FARVET SAC),Pre-clinical,Replicating viral vector,Peru,PER,6/30/2021,Pre-clinical results released March 2021,Unknown
Farmacológicos Veterinarios SAC (FARVET SAC),Pre-clinical,Replicating bacterial vector,Peru,PER,1/19/2021,Unknown,Unknown
Farmacológicos Veterinarios SAC (FARVET SAC) / Universidad Peruana Cayetano Heredia (UPCH),Pre-clinical,Protein subunit,Peru,PER,1/19/2021,Unknown,Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Phase III,Protein subunit,Russia,RUS,3/29/2021,"Phase I/II interim results published March 2021; Phase III trial began November 2020; ""Registered"" for use in Russia in October 2020; Phase I/II trial began end of July 2020",Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Pre-clinical,Protein subunit,Russia,RUS,8/31/2020,Unknown,Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Pre-clinical,Replicating viral vector,Russia,RUS,8/31/2020,Unknown,Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Pre-clinical,Replicating viral vector,Russia,RUS,8/31/2020,Unknown,Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Pre-clinical,Replicating viral vector,Russia,RUS,8/31/2020,Unknown,Unknown
"Federal Budgetary Research Institution (FBRI) State Research Center of Virology and Biotechnology ""VECTOR""",Pre-clinical,RNA-based vaccine,Russia,RUS,8/31/2020,Unknown,Unknown
Flow Pharma,Pre-clinical,Protein subunit,United States,USA,6/30/2021,Pre-clinical study results published May 2021,Unknown
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Pre-clinical,RNA-based vaccine,China,CHN,Prior to 4/20/2020,Unknown,Unknown
Fudan University / Shanghai JiaoTong University / RNACure Biopharma,Pre-clinical,RNA-based vaccine,China,CHN,Prior to 4/20/2020,Unknown,Unknown
Fundacao Oswaldo Cruz and Instituto Buntantan,Pre-clinical,Replicating viral vector,Brazil,BRA,5/27/2020,Unknown,Unknown
Gamaleya Research Institute,Phase III,Non-replicating viral vector,Russia,RUS,7/29/2021,"Final results of trials are expected to be ready by October 2021; Demonstrated efficacy based on the analysis of data from vaccinated persons announced on 4/19/2021; Started rolling review process with the European Medicines Agency (EMA) on 3/4/2021; Authorized for ""emergency use"" in 39 countries as of March 2021; Phase III interim analysis results published on 2/2/2021; ""Registered"" in Belarus in December 2020; Phase III final control point data analysis results released December 2020, interim data analysis results released November 2020; Phase III (post-registration) trial began September 2020; Phase I/2 began June 2020, results published September 2020; Russian Ministry of Health ""registered"" vaccine in August 2020, Mass production expected to begin September 2020",Russian Direct Investment Fund (RDIF)
"GeneOne
  Life Science",Phase I/II,DNA-based,South Korea,KOR,7/19/2021,Phase IIa expected to be dosed July 2021; Phase I/IIa began December 2020,Unknown
GeneOne Life Science / Houston Methodist,Pre-clinical,RNA-based vaccine,South Korea,KOR,1/5/2021,Unknown,Unknown
Generex / EpiVax,Pre-clinical,Protein subunit,United States,USA,6/30/2021,Unknown,"Beijing Youfeng Biological Technology, Ltd (Youfeng-BI)"
"Genexine Consortium (GenNBio, International Vaccine Institute, Korea Advanced Institute of Science and Technology (KAIST), Pohang University of Science and Technology (POSTECH)/ Binex/ PT Kalbe Pharma",Phase I/II,DNA-based,South Korea,KOR,7/19/2021,Phase II/III study expected to begin in Indonesia as of July 2021; Phase IIa began February 2021; Updated development plan to GX-19N formula and will reconduct Phase I/IIa study as of December 2020. Phase I of Phase I/IIa study began end of June 2020; Animal study results announced August 2020,Unknown
Gennova/ HDT Biotech Corporation,Phase I/II,RNA-based vaccine,India,IND,6/30/2021,Phase I/II began April 2021,Unknown
GeoVax / BravoVax/ NIAID/ NIH/ University of Texas Medical Branch,Pre-clinical,Non-replicating viral vector,United States,USA,1/25/2021,"Awarded a Small Business Innovative Research (SBIR) grant in January 2021 to support the ongoing design, construction, and preclinical testing in preparation for human clinical trials",National Institute of Allergy and Infectious Diseases (NIAID)/National Institutes of Health (NIH)
German Center for Infection Research (DZIF)/ IDT Biologika GmbH/ Universitätsklinikum Hamburg-Eppendorf/ Philipps University Marburg Medical Center/ Ludwig-Maximilians University of Munich,Phase I,Non-replicating viral vector,Germany,GER,7/29/2021,"Spike protein of the vector vaccine has now been modified and clinical testing will resume as of 7/16/2021; Phase I/II expected to begin July 2021; Clinical testing suspended January 2021, Phase II postponed until further notice; Phase I dosed October 2020",Unknown
GlaxoSmithKline/CureVac,Pre-clinical,RNA-based vaccine,Great Britain,GBR,6/30/2021,"Pre-clinical data released 5/13/2021; CureVac and GSK aim to develop a multi-valent candidate vaccine to address emerging variants for pandemic and endemic use; Development to begin immediately (February 2021) targeting vaccine availability in 2022, subject to regulatory approval",Unknown
"Globe Biotech Limited, Bangladesh",Pre-clinical,DNA-based,Bangladesh,BAN,11/9/2020,Unknown,Unknown
"Globe Biotech Limited, Bangladesh",Pre-clinical,Non-replicating viral vector,Bangladesh,BAN,11/9/2020,Unknown,Unknown
"Globe Biotech Limited, Bangladesh",Pre-clinical,RNA-based vaccine,Bangladesh,BAN,6/30/2021,Pre-clinical study published June 2021; Phase I/II protocol submitted to Bangladesh Medical Research Council (BMRC) on 1/17/2021 for approval to begin clinical trials; Pre-clinical data released September 2020,Unknown
Government Pharmaceutical Organization (GPO; Thailand) / Dynavax / PATH,Phase I/II,Inactivated virus,Thailand,THA,6/30/2021,Phase I/II began March 2021,Unknown
Greenlight Biosciences,Pre-clinical,RNA-based vaccine,United States,USA,5/12/2020,Unknown,Unknown
Greffex,Pre-clinical,Non-replicating viral vector,United States,USA,Prior to 4/20/2020,Unknown,Unknown
"Gritstone Oncology, Inc.",Phase I,Non-replicating viral vector,United States,USA,6/30/2021,Phase I dosed March 2021,Unknown
Guangdong Provincial Center for Disease Control and Prevention/ Gaozhou Center for Disease Control and Prevention,Phase I,Protein subunit,China,CHN,4/30/2021,Phase I began April 2021,Unknown
HaloVax (Voltron Therapeutics) / The Vaccine & Immunotherapy Center at the Massachusetts General Hospital,Pre-clinical,Unknown,United States,USA,4/21/2020,Animal study results by October 2020,Analog Devices Foundation
Heat Biologics (Zolovax)/ University of Miami/ Waisman Biomanufacturing,Pre-clinical,Protein subunit,United States,USA,8/13/2020,Animal data released August 2020,Unknown
"Helix Biogen Consult, Ogbomoso & Trinity Immonoefficient Laboratory, Ogbomoso, Oyo State, Nigeria",Pre-clinical,Protein subunit,Nigeria,NGR,6/30/2020,Unknown,Unknown
iBio / CC-Pharming,Pre-clinical,Protein subunit,United States,USA,Prior to 4/20/2020,Unknown,Unknown
Icosavax,Phase I/II,Virus-like particle,United States,USA,6/11/2021,Phase I/II began June 2021; Pre-clinical results published October 2020,Unknown
ID Pharma,Pre-clinical,Non-replicating viral vector,Japan,JAP,7/9/2020,Unknown,Unknown
"IDIBAPS- Hospital Clinic, Spain",Pre-clinical,Non-replicating viral vector,Spain,ESP,6/1/2020,Unknown,Unknown
"IDIBAPS- Hospital Clinic, Spain",Pre-clinical,RNA-based vaccine,Spain,ESP,6/1/2020,Unknown,Unknown
ImmunityBio/ NantKwest,Phase I/II,Non-replicating viral vector,United States,USA,7/19/2021,"Phase I/II/III trial expected to begin Q3 2021 and will study the efficacy, safety, and immunogenicity of ImmunityBio’s T-Cell COVID-19 vaccine as a boost in participants who have already received a spike-only antibody-based vaccine; Expanded trials to test vaccine candidate as a ‘universal boost’ in vaccinated subjects and received approval to test intranasal spray in South Africa as of May 2021; Phase I/II supplemental vaccine boost trial began April 2021; Phase Ib preliminary findings reported on 4/8/2021; Phase I interim safety data announced on 3/15/2021; Phase I dosed in South Africa and the U.S. in March 2021; FDA authorized the expansion of the active Phase I trial and a second trial to test a novel combination of T-cell-based hAd5 subcutaneous prime vaccine with a room-temperature oral or sublingual boost; Phase I interim data announced November 2020; Pre-clinical data released December, November, and July 2020; Phase I trial dosed in the U.S. in October 2020; Selected for US Operation Warp Speed in May 2020",Unknown
Immunomic Therapeutics/ EpiVax/ PharmaJet,Pre-clinical,DNA-based,United States,USA,Prior to 4/20/2020,Unknown,Unknown
ImmunoPrecise/ LiteVax BV,Pre-clinical,Protein subunit,Netherlands,NED,7/15/2020,Unknown,TRANSVAC2
Imophoron Ltd / Bristol University's Max Planck Centre,Pre-clinical,Virus-like particle,Great Britain,GBR,Prior to 4/20/2020,Unknown,Unknown
Imperial College London/ VacEquity Global Health,Phase I/II,RNA-based vaccine,Great Britain,GBR,9/10/2020,Pre-clinical results published July 2020; Phase I/II trial began June 2020,UK Government
"IMV, Inc., Canadian Center for Vaccinology at Dalhousie University, Izaak Walton Killam Health Center, Nova Scotia Health Authority, Canadian Immunization Research Network, University of Laval, Global Urgent and Advanced Research and Development in Canada",Pre-clinical,Protein subunit,Canada,CAN,6/30/2021,,"National Research Council of Canada Industrial Research Assistance Program (NRC IRAP), Atlantic Canada Opportunities Agency (ACOA), and Next Generation Manufacturing Canada (NGen)"
Indian Immunologicals Ltd/ Griffith University,Pre-clinical,Live attenuated virus,India,IND,4/28/2020,Unknown,Unknown
"Infectious Disease Research Institute/ Amyris, Inc.",Pre-clinical,RNA-based vaccine,United States,USA,11/16/2020,Phase I expected to begin mid-2021,Unknown
InnoMedica,Pre-clinical,Protein subunit,Switzerland,SUI,7/9/2020,Unknown,Unknown
Innovax / Xiamen University / GSK,Pre-clinical,Protein subunit,China,CHN,Prior to 4/20/2020,Unknown,Unknown
Inovio Pharmaceuticals/ Beijing Advaccine Biotechnology/ VGXI Inc./ Richter-Helm BioLogics/ Ology Bioservices/ International Vaccine Institute/ Seoul National University Hospital/ Thermo Fisher Scientific/ Kaneka Eurogentec,Phase II/III,DNA-based,China,CHN,6/8/2021,"Phase II preliminary results released on 5/7/2021; ex-US Global Phase III trial planning announced 4/23/2021; Study results on the human immune responses against variants of concern announced 4/15/2021; Phase I data published December 2020; Phase II dosed December 2020, as part of its Phase II/III clinical trial (INNOVATE); FDA partial clinical hold for planned Phase II/III trial reported on 9/28/2020; Phase I/IIa trial began July 2020; Animal study results released July 2020; Joined US Operation Warp Speed in June 2020; Phase I began April 2020, interim data of ongoing study released June 2020",Coalition for Epidemic Preparedness (CEPI) / Gates Foundation / US Department of Defense
Institut Pasteur/ TheraVectys,Pre-clinical,Non-replicating viral vector,France,FRA,3/28/2021,Pre-clinical results published December 2020; Animal study results released July 2020,Unknown
"Institute
  Butantan (Brazil) / Dynavax / PATH",Pre-clinical,Inactivated virus,Brazil,BRA,11/9/2020,Unknown,Unknown
"Institute of Medical Biology, Chinese Academy of Medical Sciences",Phase III,Inactivated virus,China,CHN,1/31/2021,"Phase III dosed (Malaysia) late January 2021; Phase II began June 2020; Phase I began May 2020, results released October 2020",Unknown
Institute of Vaccines and Medical Biologicals (IVAC; Vietnam) / Dynavax / PATH,Phase I/II,Inactivated virus,Vietnam,VIE,4/28/2021,"Phase I/II began March 2021, Phase I is expected to be completed by end of May 2021",Unknown
Instituto Finlay de Vacunas,Phase III,Protein subunit,Cuba,CUB,7/19/2021,Phase III efficacy data announced 7/8/2021; Phase III preliminary data announced on 6/19/2021; Phase I/II pediatric study (ages 3-18 years) began June 2021; Cuba began rolling out the vaccine in a mass campaign in May 2021; Phase III began March 2021; Phase II began December 2020; Phase I began October 2020,Unknown
Instituto Finlay de Vacunas,Phase I/II,Protein subunit,Cuba,CUB,5/14/2021,Phase I preliminary report released March 2021; Phase I/II began August 2020,Unknown
Intravacc/ Wageningen Bioveterinary Research/Utrecht Univ.,Pre-clinical,Replicating viral vector,Netherlands,NED,5/19/2020,Unknown,Unknown
Intravacc/Epivax,Pre-clinical,Protein subunit,United States,USA,5/19/2020,Unknown,Unknown
Intravacc/Epivax,Pre-clinical,Protein subunit,United States,USA,6/30/2021,Pre-clinical data announced April 2021,Unknown
iosBIO (formerly Stabilitech Biopharma Ltd),Pre-clinical,Non-replicating viral vector,,,3/28/2021,Unknown,Unknown
IrsiCaixa AIDS Research/ IRTA-CReSA/ Barcelona Supercomputing Centre/ Grifols,Pre-clinical,Virus-like particle,Spain,ESP,6/23/2020,Unknown,Unknown
ISR Immune System Regulation,Pre-clinical,Unknown,Sweden,SWE,Prior to 4/20/2020,"Animal study results expected in Q2 2020, Phase I begins Q4 2020",Unknown
"Israel
  Institute for Biological Research/ Weizmann Institute of Science",Phase I/II,Replicating viral vector,Israel,ISR,5/14/2021,Phase III expected to begin spring 2021; Phase I began November 2020 and Phase II began December 2020,Unknown
Izmir Biomedicine and Genome Center,Pre-clinical,Protein subunit,Turkey,TUR,7/9/2020,Unknown,Unknown
Janssen Pharmaceutical Companies/ Beth Israel Deaconess Medical Center/ Emergent BioSolutions/ Catalent/ Biological E/ Grand River Aseptic Manufacturing (GRAM)/ Sanofi/ Merck,Authorized,Non-replicating viral vector,United States,USA,7/29/2021,"Phase I/IIa sub-study results published 7/14/2021; Johnson & Johnson statement on COVID-19 vaccine released 7/12/2021; Data on neutralizing activity against emerging variants announced 7/1/2021; U.K. MHRA granted ""conditional marketing authorization"" on 5/28/2021; CDC and FDA lift recommended pause on vaccine use in U.S. on 4/23/2021; Phase III ENSEMBLE primary data published on 4/21/2021; CDC and FDA recommended a pause on vaccine use in the U.S. as of 4/13/2021; Phase IIa trial expanded to include adolescents 12-17 years of age as of 4/2/2021; WHO issued ""emergency use listing"" on 3/12/2021; Granted Conditional Marketing Authorization by European Commission on 3/11/2021; Granted ""Interim Order (IO) authorization"" for emergency use by Health Canada on 3/5/2021; U.S. CDC's Advisory Committee on Immunization Practices (ACIP) has recommended the first single-shot COVID-19 vaccine for individuals 18 years of age and older on 2/28/2021; U.S. FDA issued ""emergency use authorization"" on 2/27/2021; Submitted ""emergency use listing"" to the World Health Organization (WHO) on 2/19/2021; Submitted ""conditional marketing authorisation application"" to the European Medicines Agency (EMA) on 2/16/2021; Janssen submitted application for ""emergency use authorization"" to the U.S. FDA on 2/4/2021; Phase III interim analysis results announced 1/29/2021; Phase I/IIa interim results published 1/13/2021; Phase III trial to study the safety and efficacy of a two-dose regimen began 11/15/2020 (ENSEMBLE 2); Phase III trial (ENSEMBLE) resumed recruitment on 10/23/2020, fully enrolled with ~45,000 participants as of 12/17/2020, interim data expected by the end of January 2021; Janssen Pharmaceutical Companies of Johnson & Johnson voluntarily paused dosing to allow independent review of safety data on 10/12/2020; Phase III trial (ENSEMBLE) began and study protocol released September 2020; Phase I/IIa began end of July 2020, interim results released September 2020; Animal study results published July and September 2020; Selected for US Operation Warp Speed in February 2020 and awarded funding in August 2020",Biomedical Advanced Research and Development Authority (BARDA)
Kazakh National Agrarian University,Pre-clinical,Protein subunit,Kazakhstan,KAZ,11/10/2020,Unknown,Unknown
"Kazakh National Agrarian University, Kazakhstan/ National Scientific Center for Especially Dangerous Infections",Pre-clinical,Protein subunit,Kazakhstan,KAZ,11/10/2020,Unknown,Unknown
Kentucky BioProcessing (British American Tobacco),Phase I/II,Protein subunit,United States,USA,5/31/2021,"Phase I/II began recruiting December 2020, results expected mid-2021",Unknown
KM Biologics,Phase I/II,Inactivated virus,Japan,JAP,5/31/2021,Phase I/II study began March 2021,Unknown
Kocak Farma Ilac ve Kimya San. A.S.,Phase I,Inactivated virus,Turkey,TUR,4/30/2021,Phase I began March 2021,Unknown
KU Leuven,Pre-clinical,Replicating viral vector,Belgium,BEL,5/4/2020,Unknown,Unknown
"Laboratorio Avi-Mex/ National Council of Science and Technology, Mexico/ Agencia Mexicana de Cooperación Internacional para el Desarrollo (AMEXID)",Phase I,Inactivated virus,,,6/30/2021,Phase I began May 2021,Unknown
"LakePharma, Inc.",Pre-clinical,Protein subunit,United States,USA,5/4/2020,Unknown,Unknown
Lomonosov Moscow State University,Pre-clinical,Protein subunit,Russia,RUS,5/27/2020,Unknown,Unknown
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Icahn School of Medicine at Mount Sinai,Phase I/II,Replicating viral vector,Thailand,THA,3/28/2021,Phase I/II began March 2021,Unknown
Mahidol University/ The Government Pharmaceutical Organization (GPO)/ Siriraj Hospital,Pre-clinical,Virus-like particle,Thailand,THA,6/30/2020,Unknown,Unknown
"Massachusetts Eye and Ear/ AveXis, a Novartis Company/  Viralgen/ Aldevron/ Catalent/ Penn Medicine",Pre-clinical,Non-replicating viral vector,United States,USA,1/29/2021,Pre-clinical results released January 2021; Phase I to begin second half of 2020,Gates Foundation
Max-Planck Institute for Dynamics of Complex Technical Systems,Pre-clinical,Virus-like particle,Germany,GER,11/9/2020,Unknown,Unknown
Max-Planck Institute of Colloids and Interfaces,Pre-clinical,Protein subunit,Germany,GER,11/10/2020,Unknown,KHAN-1 Technology Transfer Fund I GmbH & Co KG
Max-Planck Institute of Colloids and Interfaces,Pre-clinical,RNA-based vaccine,Germany,GER,11/9/2020,Unknown,KHAN-1 Technology Transfer Fund I GmbH & Co KG
"Medicago
  Inc./ GSK",Pre-clinical,Virus-like particle,Canada,CAN,7/14/2020,Unknown,Unknown
Medicago Inc./ Dynavax,Pre-clinical,Virus-like particle,Canada,CAN,7/10/2020,Phase I to start mid-July 2020,Unknown
Medicago Inc./ GlaxoSmithKline,Phase II/III,Virus-like particle,Canada,CAN,5/24/2021,Phase II interim results released May 2021; Health Canada initiated review of the Interim Order (IO) rolling submission on 4/19/2021; Phase III portion of the ongoing Phase II/III trial began March 2021;Phase II portion of the Phase II/III trial dosed December 2020; Phase II/III began recruiting November 2020; Phase I interim results released November 2020; Phase I began July 2020,Unknown
Medigen Vaccine Biologics Corp/ NIAID/ Dynavax,Phase II,Protein subunit,United States,USA,7/29/2021,"Phase III expected to complete the recruitment (1,000 participants) by Q3 2021; Taiwan granted EUA approval on 7/19/2021, clinical trials are ongoing; Phase II interim analysis results released 6/10/21; Phase II study in elderly adults (65 years and older) began May 2021; Booster trial with third dose began May 2021; Phase II second dose vaccination completed on 4/28/2021; Phase I interim analysis results announced 4/7/2021; Phase II dosed January 2021; Phase I dosed in early October 2020; Received conditional approval for clinical testing on Aug 31 and was given full approval on Sept 30; Pre-clinical data released August 2020 and published November 2020",Unknown
Mediphage Bioceuticals/ University of Waterloo/ Lambton College,Pre-clinical,DNA-based,Canada,CAN,9/23/2020,Unknown,Unknown
Mehmet Ali Aydinlar University/ Acıbadem Labmed Health Services A.S.,Pre-clinical,Live attenuated virus,Turkey,TUR,7/9/2020,Unknown,Unknown
Meissa Vaccines ,Phase I,Live attenuated virus,United States,USA,5/17/2021,Phase I enrollment began March 2021,Unknown
MIGAL Galilee Research Institute,Pre-clinical,Protein subunit,Israel,ISR,Prior to 4/20/2020,Unknown,Unknown
Moderna/ National Institute of Allergy and Infectious Diseases (NIAID)/ Biomedical Advanced Research and Development Authority (BARDA)/ Lonza/ Catalent/ Rovi/ Medidata/ BIOQUAL/ Baxter BioPharma Solutions/ Sanofi/ Recipharm,Authorized,RNA-based vaccine,United States,USA,7/6/2021,"India granted ""Emergency Use Authorization"" on 6/29/2021; Clinical update on mRNA-1273's neutralizing activity against emerging variants announced 6/29/2021; Submitted authorization application to Swissmedic for use in adolescents on 6/14/2021; Filed for authorization with U.S. FDA for use in adolescents (12-18 years of age) on 6/10/2021; Filed for authorization with Health Canada for use in adolescents on 6/7/2021; Filed for conditional marketing approval (CMA) with the European Medicines Agency (EMA) for use in adolescents on 6/7/2021; Initiated rolling submission process with the U.S. FDA for a Biologics License Application (BLA) on 6/1/2021; Phase II/III study in adolescents met its primary immunogenicity endpoint as of 5/25/2021, data is expected to be submitted to regulators globally in early June 2021; Phase II initial booster data against variants announced 5/5/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 4/30/2021; Antibody persistence data published 4/6/2021; Phase II/III study (KidCOVE) dosed in pediatric population less than 12 years of age on 3/16/2021; Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed on 3/15/2021; First participants dosed with modified COVID-19 vaccines, designed to address the potential need for booster vaccine candidates, in an amendment to the ongoing Phase II clinical study on 3/10/21; Provided strategy update for addressing SARS-CoV-2 variants of concern, including a variant-specific booster candidate (mRNA-1273.351) based on the B.1.351 variant first identified in the Republic of South Africa, on 2/24/2021; Results from an in vitro study on neutralization of variants of SARS-CoV-2 by mRNA-1273 vaccine-elicited sera announced January 2021; Phase I/II dosed in Japan (TAK-919) on 01/21/2021; Switzerland ""authorized"" on 01/12/2021; U.K. MHRA granted ""temporary authorization"" on 01/08/2021; European Commission granted a ""conditional marketing authorization"" on 01/06/2021; Israel granted ""authorization to import"" on 01/04/2021; Phase III interim safety and primary efficacy results published on 12/30/2020; Health Canada ""authorized"" on 12/23/2020; U.S. FDA issued ""emergency use authorization"" on 12/18/2020; Phase II/III study in adolescents ages 12 to less than 18 dosed on 12/10/2020; Submitted Emergency Use Authorization (EUA) request to the U.S. FDA on 11/30/2020; Phase III primary efficacy analysis results announced 11/30/2020; European Medicines Agency (EMA) started rolling review on 11/17/2020; Phase III interim analysis results announced 11/16/2020; Swissmedic started rolling review on 11/13/2020; UK Medicines and Healthcare products Regulatory Agency (MHRA) started rolling review on 10/27/2020; EMA confirmed marketing authorization submission eligibility on 10/14/2020; Health Canada rolling submission initiated on 10/13/2020; Study protocol for late-stage clinical trials released September 2020; Phase I interim data from older adult cohorts released Aug 2020 and published Sep 2020; Phase III COVE study began July 2020, completed enrollment on 10/22/2020; Animal study results published July/Aug 2020; Phase I interim results published July 2020; FDA fast track designation granted May 2020; Selected for US Operation Warp Speed in April 2020",Coalition for Epidemic Preparedness (CEPI)/ Biomedical Advanced Research and Development Authority (BARDA)
Moderna/National Institute of Allergy and Infectious Diseases (NIAID),Phase I,RNA-based vaccine,United States,USA,7/6/2021,Initial booster data announced May 2021; Phase I began March 2021,Unknown
"ModernaTX, Inc.",Phase II/III,RNA-based vaccine,United States,USA,6/30/2021,Phase II/III began May 2021,Unknown
"ModernaTX, Inc.",Phase I,RNA-based vaccine,United States,USA,7/6/2021,"Phase I study of next generation COVID-19 vaccine candidate, mRNA-1283, dosed March 2021",Unknown
"MOGAM Institute for Biomedical Research, GC Pharma",Pre-clinical,Protein subunit,South Korea,KOR,11/16/2020,Unknown,Unknown
Monash Institute of Pharmaceutical Sciences (MIPS)/ Peter Doherty Institute for Infection and Immunity (Doherty Institute),Pre-clinical,RNA-based vaccine,Australia,AUS,7/29/2021,Phase I expected to begin October 2021; Preliminary trial results are expected in the first half of 2022,"mRNA Victoria, the agency of the Australian State of Victoria Government"
Mynvax,Pre-clinical,Protein subunit,India,IND,7/15/2020,Unknown,Unknown
Nanogen Pharmaceutical Biotechnology,Phase III,Protein subunit,Vietnam,VIE,6/18/2021,Phase III began June 2021; Phase II began February 2021; Phase I began December 2020,Unknown
"National Research Centre, Egypt",Pre-clinical,DNA-based,Egypt,EGY,6/30/2020,Unknown,Unknown
"National Research Centre, Egypt",Pre-clinical,Non-replicating viral vector,Egypt,EGY,6/30/2020,Unknown,Unknown
"National Research Centre, Egypt",Pre-clinical,Protein subunit,Egypt,EGY,6/30/2020,Unknown,Unknown
"National Center for Genetic Engineering and Biotechnology (BIOTEC)/ GPO, Thailand",Pre-clinical,Non-replicating viral vector,Thailand,THA,6/1/2020,Unknown,Unknown
"National Institute of Chemistry, Slovenia",Pre-clinical,DNA-based,Slovenia,SLO,11/9/2020,Unknown,Unknown
"National Research Centre, Egypt",Pre-clinical,Inactivated virus,Egypt,EGY,6/30/2021,Pre-clinical study results published March 2021,Unknown
"National Vaccine and Serum Institute, China",Phase I/II,Protein subunit,China,CHN,6/30/2021,Phase I/II began recruiting April 2021,Unknown
"Navarrabiomed, Oncoimmunology group",Pre-clinical,Virus-like particle,Spain,ESP,6/1/2020,Unknown,Unknown
Neo7Logix,Pre-clinical,Protein subunit,United States,USA,11/16/2020,Unknown,Unknown
Neovii/Tel Aviv University,Pre-clinical,Protein subunit,Israel,ISR,5/19/2020,Unknown,Unknown
NidoVax,Pre-clinical,Unknown,United States,USA,6/18/2020,Unknown,Unknown
Novavax/Emergent Biosolutions/ Praha Vaccines/ Biofabri/ Fujifilm Diosynth Biotechnologies/ FDB/ Serum Institute of India/ SK bioscience/ Takeda Pharmaceutical Company Limited/ AGC Biologics/ PolyPeptide Group/ Endo,Phase III,Protein subunit,United States,USA,7/6/2021,"Phase III (U.K. trial) final analysis results published 6/30/2021; Phase III efficacy data released 6/14/2021; Updated PREVENT-19 trial protocol released on 5/10/2021; Announced preclinical data from NanoFlu/NVX-CoV2373 combination vaccine study on 5/10/2021; Initiated a pediatric expansion (12-17 years of age) of its Phase III clinical trial on 5/3/2021; Announced participation in Phase II clinical trial called ""Comparing COVID-19 Vaccine Schedule Combinations – Stage 2"" (Com-COV2) on 4/14/2021; Announced the initiation of crossover arms in two ongoing clinical trials on 4/5/2021; Phase III (UK) and Phase IIb ( South Africa) final efficacy results released 3/11/2021; Phase I/II trial dosed in Japan on 2/26/2021; Phase III trial (PREVENT-19) completed enrollment in the US and Mexico on 2/22/2021; Announced the start of the rolling review process with several regulatory agencies worldwide on 2/4/2021, including the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada; Phase III (UK) and Phase IIb ( South Africa) interim results released 1/28/2021; Phase III trial (PREVENT-19) initiated in the US and Mexico in December 2020, trial protocol released on website; FDA granted Fast Track Designation on 11/9/2020; Phase III dosed in the UK in October 2020, trial protocol released on website, interim data expected to be released in Q1 2021; Phase IIb trial began Aug 2020; Selected for US Operation Warp Speed July 2020; Phase I/II began end of May 2020, interim data expected to be released on 10/30/2020; Animal study & preliminary Phase I results released Aug 2020, Phase I results published Sept 2020",Coalition for Epidemic Preparedness (CEPI)/ US Department of Defense/ Gates Foundation
Ohio State University/ Kazakh National Agrarian University,Pre-clinical,Protein subunit,Kazakhstan,KAZ,11/10/2020,Unknown,Unknown
OncoGen,Pre-clinical,Protein subunit,Romania,ROU,Prior to 4/20/2020,Unknown,Unknown
OncoSec Medical Incorporated / Providence Cancer Institute,Phase I,DNA-based,United States,USA,2/2/2021,Phase I dosed January 2021,Unknown
OPENCORONA Project: Karolinska Institute/ Justus Liebig University Giessen/ Public Health Agency of Sweden (FoHM)/ IGEA/ Cobra Biologics/ Adlego Biomedical/ Region Stockholm,Pre-clinical,DNA-based,Sweden,SWE,9/23/2020,Phase I expected to begin in 2020,European Commission (Horizon 2020 Program)
Oragenics (Noachis Terra)/ Aragen Bioscience,Pre-clinical,Unknown,United States,USA,9/28/2020,Phase I expected to start in early 2021,Unknown
"Osaka University / BIKEN / National Institutes of Biomedical Innovation, Japan",Pre-clinical,Protein subunit,Japan,JAP,Prior to 4/20/2020,Unknown,Unknown
Osaka University / BIKEN / NIBIOHN,Pre-clinical,Inactivated virus,Japan,JAP,Prior to 4/20/2020,Unknown,Unknown
Osaka University/ AnGes/ Takara Bio/ Cytiva/ Brickell Biotech,Phase II/III,DNA-based,Japan,JPN,1/31/2021,"Phase II/III trial began December 2020; Pre-clinical study results released October 2020; Phase I/II trials began end of June (AG0301) and August (AG0302) 2020, results expected during Q1 2021",Unknown
OSE  Immunotherapeutics/ Cenexi,Phase I,Protein subunit,France,FRA,7/6/2021,Phase I began May 2021; Pre-clinical results  released in August 2020,Unknown
OSIVAX,Pre-clinical,Virus-like particle,France,FRA,7/9/2020,Unknown,European Innovation Council (EIC)
PDS Biotechnology,Pre-clinical,Protein subunit,United States,USA,6/30/2021,Phase I/II is expected to to begin by Q2/3 2021,"The Ministry of Science, Technology and Innovation of Brazil (MCTI)"
People's Liberation Army (PLA) Academy of Military Sciences/ Walvax Biotech,Phase II,RNA-based vaccine,China,CHN,4/30/2021,Phase III expected to begin late May 2021; Phase II began January 2021; Phase Ib began end of October 2020; Pre-clinical results published September 2020; Phase I trial began end of June 2020,Unknown
Precision Vaccines Program at Boston Children's Hospital,Pre-clinical,Unknown,United States,USA,Prior to 4/20/2020,Unknown,Unknown
Providence Therapeutics Holdings Inc.,Phase I,RNA-based vaccine,Canada,CAN,5/28/2021,Phase II expected to begin June 2021; Pre-clinical results released May 2021; Phase I interim data announced May 2021; Phase I dosed January 2021,Unknown
Quadram Institute Biosciences,Pre-clinical,Protein subunit,Great Britain,GBR,5/12/2020,Unknown,Unknown
Radboud University,Phase I,Virus-like particle,Netherlands,NED,4/30/2021,Phase I of I/II study began March 2021,Unknown
Razi Vaccine and Serum Research Institute,Phase II,Protein subunit,Iran,IRI,6/18/2021,Phase II began April 2021; Phase I began February 2021,Unknown
ReiThera/ Leukocare/ Univercells/ National Institute of Infectious diseases Lazzaro Spallanzani,Phase II/III,Non-replicating viral vector,Italy,ITA,7/19/2021,"Phase II preliminary data announced July 2021; Phase II/III (COVITAR) study began March 2021; Phase I advanced to second set of three cohorts (aged 65-85 years) in November 2020; Phase I began August 2020, completed the first set of three cohorts (aged 18-55 years), preliminary results announced November 2020",Unknown
"Research Institute for Biological Safety Problems, Rep of Kazakhstan",Pre-clinical,Protein subunit,Kazakhstan,KAZ,8/3/2020,Unknown,Unknown
"Research Institute for Biological Safety Problems, Republic of Kazakhstan",Phase III,Inactivated virus,Kazakhstan,KAZ,4/28/2021,"Kazakhstan lauched nationwide vaccine roll out as of 4/27/2021; Kazakhstan granted ""temporary registration for nine months"" as of 1/13/2021; Phase III began December 2020; Phase I/II began September 2020",Unknown
"RNAimmune, Inc.",Pre-clinical,RNA-based vaccine,United States,USA,5/4/2020,Unknown,Unknown
Saiba GmbH,Pre-clinical,Virus-like particle,Switzerland,SUI,Prior to 4/20/2020,Unknown,Unknown
Sanofi Pasteur/ GSK,Phase III,Protein subunit,France,FRA,7/29/2021,EMA began rolling review on 7/20/2021; Phase III began end of May 2021; Phase II interim results released May 2021; Phase II with refined antigen formulation began February 2021; Phase I/II interim safety and immunogenicity results released January 2021; Phase IIb expected to begin February 2021; Phase I/II interim results announced December 2020; Phase I/II began September 2020; Selected for US Operation Warp Speed in April 2020 and awarded funding in July 2020,Biomedical Advanced Research and Development Authority (BARDA)/ US Department of Health and Human Services (HHS)/ US Department of Defense (DoD)
Sanofi Pasteur/ Translate Bio,Phase I/II,RNA-based vaccine,France,FRA,3/28/2021,"Phase I/II began March 2021, interim results expected in 3Q 2021; Pre-clinical results released October 2020",Unknown
Scancell/ University of Nottingham/ Nottingham Trent University,Pre-clinical,DNA-based,Sweden,SWE,1/19/2021,Phase I COVIDITY clinical trial expected to start as soon as possible during 2021,Unknown
Scientific and Technological Research Council of Turkey (TUBITAK),Phase I,Inactivated virus,Turkey,TUR,4/30/2021,Phase I began end of April 2021,Unknown
Scientific and Technological Research Council of Turkey (TÜBITAK)/ Middle East Technical University/ Bilkent University,Phase I,Virus-like particle,Turkey,TUR,4/28/2021,Phase II expected to begin early June 2021; Phase I dosed end of March 2021,Unknown
Selcuk University,Pre-clinical,Inactivated virus,Turkey,TUR,9/23/2020,Unknown,Unknown
Selcuk University,Pre-clinical,RNA-based vaccine,Turkey,TUR,7/9/2020,Unknown,Unknown
SENAI CIMATEC/ HDT Bio Corp,Pre-clinical,RNA-based vaccine,Brazil,BRA,7/6/2021,Phase I expected to begin July 2021,Unknown
Serum Institute of India/ Accelagen Pty/ SpyBiotech,Phase I/II,Virus-like particle,India,IND,1/31/2021,Phase I of follow up Phase I/II clinical trial adjuvanted with CpG 1018 dosed December 2020; Phase I/II began September 2020,Unknown
Shenzhen Geno-Immune Medical Institute,Phase I/II,Non-replicating viral vector,China,CHN,1/31/2021,Phase I/II reportedly began March 2020,Unknown
Shenzhen Geno-Immune Medical Institute,Phase I,Replicating viral vector,China,CHN,1/31/2021,Phase I reportedly began February 2020,Unknown
"Shenzhen Kangtai Biological Products Co.,Ltd./ Beijing Minhai Biotechnology Co., Ltd.",Phase III,Inactivated virus,China,CHN,6/22/2021,"Phase III began June 2021; Received early approval for ""emergency use"" in China in May 2021; Phase I/II results announced April 2021; Phase I/II study began October 2020",Unknown
Shifa Pharmed Industrial Co,Phase II/III,Inactivated virus,Iran,IRI,3/18/2021,Iran granted emergency use authorization on 6/14/2021; Phase II/III trial in adults 18-75 years of age began March 2021; Phase I trial in adults 51-75 years of age began March 2021; Phase I trial in adults 18-50 years of age began December 2020,Unknown
"Shionogi & Co., Ltd./ National Institute of Infectious Disease, Japan",Phase I/II,Protein subunit,Japan,JAP,1/5/2021,Phase I/II began December 2020,Japan Agency for Medical Research and Development
Sinovac/ Dynavax,Pre-clinical,Inactivated virus,China,CHN,4/28/2020,Unknown,Unknown
Sinovac/ Instituto Butantan/ Bio Farma,Phase III,Inactivated virus,China,CHN,7/6/2021,"Phase I/II clinical trials results in healthy children and adolescents aged 3-17 in China published 6/28/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 6/1/2021; Summary of clinical trial data released on 4/3/2021; Emergency use approval, or conditional marketing authorization, has been granted by over 30 countries as of 4/1/2021; Malaysia granted ""conditional approval"" on 3/2/2021; China's NMPA granted ""conditional marketing authorization"" on 2/8/2021; Phase III results (Brazil, Turkey, Indonesia, Chile) announced on 2/5/2021; Phase I/II safety, tolerability, and immunogenicity data in adults aged 60 years and older published on 2/3/2021; Sinovac filed for ""conditional market authorization"" with China’s National Medical Products Administration (NMPA) on 2/3/2021; Chile granted ""emergency use"" approval on 1/20/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Turkey granted ""emergency use authorization"" on 1/31/2021; Indonesia granted ""emergency use approval"" on 01/11/2021; Phase III efficacy results (Brazil) released early January 2021; Phase I/II complete analysis results published 11/17/2020; Phase III trial resumed in Brazil on 11/11/2020, Phase III trial suspended in Brazil on 11/09/2020; Received approval for Phase I/II trial in adolescents and children in September 2020; Phase III trial began end of July 2020; Phase II began June 2020, mid-phase II results released August 2020; Preliminary results from Phase I/II trials released June and September 2020 (aged 60+) 2020; Received early approval for ""emergency use"" in China (Aug 2020)",Unknown
SK Biosciences/ GSK/ Institute for Protein Design (IPD) at the University of Washington (UW),Phase I/II,Protein subunit,United States,USA,5/27/2021,Phase III IND is expected to be submitted  to the Korean Ministry of Food and Drug Safety within next month (as of May 2021); Phase I/II began February 2021,Gates Foundation/ Coalition for Epidemic Preparedness (CEPI)
Soligenix/ University of Hawaii at Mānoa,Pre-clinical,Protein subunit,United States,USA,8/27/2020,Pre-clinical testing results released in July 2020,"Soligenix, Inc."
Sorrento Therapeutics,Pre-clinical,Protein subunit,United States,USA,8/17/2020,Animal study results released July 2020,Unknown
St. Petersburg Scientific Research Institute of Vaccines and Serums,Pre-clinical,Protein subunit,Russia,RUS,Prior to 4/20/2020,Unknown,Unknown
"Statens Serum Institute, Denmark",Pre-clinical,DNA-based,Denmark,DEN,11/16/2020,Phase I is expected to start in late 2020 or early 2021,Folketing's Finance Committee
Symvivo,Phase I,DNA-based,Canada,CAN,7/29/2021,Phase I dosed November 2020,National Research Council of Canada Industrial Research Assistance Program (NRC IRAP)
Takis/ Applied DNA Sciences/ Evvivax/ Rottapharm Biotech,Phase I/II,DNA-based,United States,USA,3/28/2021,"Phase I/II began March 2021, announced the authorization of the clinical trial by the Italian Medicines Agency (AIFA) on 2/3/2021; Pre-clinical results released in May and July 2020",Unknown
Tampere University,Pre-clinical,Protein subunit,Finland,FIN,11/10/2020,Unknown,Unknown
Tampere University,Pre-clinical,Virus-like particle,Finland,FIN,11/9/2020,Unknown,Unknown
Tetherex Pharmaceuticals Corporation,Pre-clinical,Non-replicating viral vector,Great Britain,GBR,4/30/2021,Phase I expected to begin June 2021,Unknown
"The Lancaster University, UK",Pre-clinical,Replicating viral vector,Great Britain,GBR,5/19/2020,Unknown,Unknown
The University of Hong Kong/ Xiamen University/ Wantai Biological Pharmacy,Phase I/II,Replicating viral vector,China,CHN,4/12/2021,Phase I expected to begin in Hong Kong in April 2021; Phase I/II began in China during Fall 2020; Approved for clinical trials in September 2020,Coalition for Epidemic Preparedness (CEPI)
Tonix Pharma / Southern Research,Pre-clinical,Replicating viral vector,United States,USA,6/30/2021,Phase I expected to begin during second half of 2021; Preliminary pre-clinical results reported on 3/17/2021,Unknown
Tulane University,Pre-clinical,Unknown,United States,USA,Prior to 4/20/2020,Unknown,Unknown
UMN Pharma (Shionogi),Pre-clinical,Protein subunit,Japan,JAP,5/10/2020,Phase I to start by end of 2020,Japan Agency for Medical Research and Development
United Biomedical (UBI)/ c19,Pre-clinical,Unknown,United States,USA,9/2/2020,,Unknown
University Hospital Tuebingen,Phase I,Protein subunit,Germany,GER,2/27/2021,Phase I began December 2020,Unknown
University Medical Center Groningen/ Akston Biosciences Corporation/ LakePharma,Phase I/II,Protein subunit,United States,USA,4/13/2021,Phase I/II dosed April 2021,Unknown
University of Alberta,Pre-clinical,Protein subunit,Canada,CAN,Prior to 4/20/2020,Unknown,Unknown
"University of California, Los Angeles (Horwitz Lab)",Pre-clinical,Replicating bacterial vector,United States,USA,5/10/2020,Unknown,Unknown
"University of California, San Diego",Pre-clinical,Protein subunit,United States,USA,4/28/2020,Unknown,National Science Foundation (Rapid Response Research [RAPID] grant)
University of Cambridge/ DIOSynVax/ PharmaJet,Pre-clinical,DNA-based,Great Britain,GBR,10/28/2020,Phase I expected to begin late fall 2020 or early 2021,Innovate UK
University of Georgia/ University of Iowa,Pre-clinical,Non-replicating viral vector,United States,USA,4/28/2020,Unknown,Unknown
University of Helsinki/ University of Eastern Finland/ Rokote Laboratories Finland Ltd,Pre-clinical,Non-replicating viral vector,Finland,FIN,3/28/2021,Unknown,Unknown
University of Manitoba,Pre-clinical,Replicating viral vector,Canada,CAN,11/9/2020,Unknown,Unknown
University of Manitoba,Pre-clinical,Virus-like particle,Canada,CAN,11/9/2020,Unknown,Unknown
"University of Oxford, Oxford Biomedica, Vaccines Manufacturing and Innovation Centre, Pall Life Sciences, Cobra Biologics, HalixBV, Advent s.r.l., Merck KGaA, the Serum Institute, Vaccitech, Catalent, CSL, and AstraZeneca/IQVIA",Authorized,Non-replicating viral vector,Great Britain,GBR,7/6/2021,"Tolerability and immunogenicity results after a late second dose or a third dose released on 6/28/2021; Real-world data on vaccine effectiveness against hospitalizations due to the Delta variant released 6/14/2021; Japan granted authorization for ""emergency use"" on 5/21/2021; EMA updated guidance on very rare side effects announced 4/7/2021; Phase II dosing paused in children between the ages of 6 and 17 years pending MHRA review as of 4/6/2021; Phase III primary analysis (U.S. trial) results announced 3/25/2021; Phase III interim analysis (U.S. trial) results announced 3/22/2021; World Health Organization (WHO) granted Emergency Use Listing (EUL) on 2/15/2021; Phase II study in children between the ages of 6 and 17 years expected to begin in February 2021; Phase III (U.K., Brazil) and Phase I/II (U.K., South Africa) analyses data released on 2/3/2021; European Union (EU) granted ""conditional marketing authorisation"" on 1/29/2021; Brazil granted ""temporary authorization for emergency use"" on 1/17/2021; Pakistan granted ""emergency use authorization"" on 1/15/2021; India granted ""emergency use authorisation"" as well as Dominican Republic, El Salvador, Mexico and Morocco as of 1/6/2021; Argentina authorized under ""emergency registration"" on 12/30/2020;  U.K. ""authorised for emergency supply"" on 12/30/2020; Phase I/II data (w/ booster dose) published on 12/17/2020; Phase III trials interim analysis results published 12/8/2020; Phase II/III (COV002) and Phase III (COV003) trial pooled interim analysis results released on 11/23/2020; Phase II/III trial interim results released Nov 2020; Study protocol for late-stage clinical trials released September 2020; AstraZeneca clinical trials resumed globally (in the UK on 9/14/2020, Brazil and South Africa on 9/15/2020, Japan on 10/2/2020, and the US on 10/23/2020); AstraZeneca voluntarily paused vaccination to allow independent review of safety data on 9/8/2020; Phase III trial began Jun 2020 and expanded into US in Aug 2020; Phase II/III began May 2020; Phase I/II trial interim results released Jul 2020; Selected for US Operation Warp Speed in May 2020","Coalition for Epidemic Preparedness Innovations (CEPI)/ UK Government/ Biomedical Advanced Research and Development Authority (BARDA)/ Gavi, the Vaccine Alliance"
University of Pittsburgh,Pre-clinical,Protein subunit,United States,USA,Prior to 4/20/2020,Phase I to start as early as June 2020,Unknown
"University of San Martin and CONICET, Argentina",Pre-clinical,Protein subunit,Argentina,ARG,6/12/2020,Unknown,Unknown
University of Sao Paulo,Pre-clinical,Virus-like particle,Brazil,BRA,5/19/2020,Unknown,Unknown
University of Virginia,Pre-clinical,Protein subunit,United States,USA,7/8/2020,Unknown,Unknown
University of Western Ontario,Pre-clinical,Replicating viral vector,Canada,CAN,Prior to 4/20/2020,Unknown,Unknown
University of Wisconsin-Madison / FluGen/ Bharat Biotech,Pre-clinical,Replicating viral vector,India,IND,5/4/2020,Start Phase I trial in fall 2020,Unknown
Vabiotech,Pre-clinical,Protein subunit,Vietnam,VIE,11/16/2020,Unknown,Unknown
"Valneva/ Dynavax/ National Institute for Health Research, United Kingdom",Phase III,Inactivated virus,United States,USA,6/18/2021,Phase III began April 2021; Phase I/II data announced April 2021; Phase I/II began December 2020,Unknown
Valo Therapeutics Ltd/ ImmunoScape,Pre-clinical,Non-replicating viral vector,Finland,FIN,3/28/2021,Unknown,Unknown
Vault Pharma/ University of California Los Angeles,Pre-clinical,Unknown,United States,USA,6/17/2020,Unknown,Unknown
Vaxart/ Emergent BioSolutions,Phase I,Non-replicating viral vector,United States,USA,4/28/2021,"Phase II expected to begin Q2 2021; Phase I preliminary data announced 2/3/2021; Phase I dosed October 2020; FDA clearance for Phase I trial received September 2020, recruiment expected to begin September 2020; Pre-clinical results released September 2020; Data from ongoing animal challenge study released October and November 2020",Unknown
VaxForm,Pre-clinical,Protein subunit,United States,USA,6/30/2021,Phase I expected to begin June 2021,Unknown
Vaxil Bio,Pre-clinical,Protein subunit,Canada,CAN,6/30/2021,"Vaxil has put its COVID-19 vaccine work on temporary hold as of May 31, 2021",Unknown
Vaxine Pty Ltd/ Flinders University/ Oracle/ Medytox/ Sypharma/ Oxford Expression Technologies,Phase II,Protein subunit,Australia,AUS,7/19/2021,Phase II dosed June 2021; Phase II and III will be initiated in Iran in the coming weeks as of May 2021; Phase I trial dosed July 2020,Innovate UK/ Australian Government
"Vaxxinity, Inc. (formerly COVAXX and United Neuroscience)/ University of Nebraska Medical Center (UNMC)/ DASA/ United Biomedical Inc. Asia",Phase II,Protein subunit,United States,USA,8/3/2021,"Phase I study extended with one booster dose in July 2021; Phase II/III trials expected to begin in Brazil, India, and other countries in Q2 2021; Phase I interim data announced 2/8/2021; Phase II began (Taiwan) February 2021; Phase II clinical trials granted conditional approval by Taiwan's Ministry of Health and Welfare on 1/29/2021; Phase I began (Taiwan) September 2020; Large scale human efficacy clinical trials expected to be conducted in Brazil and the US",Ministry of Health and Welfare in Taiwan
VBI Vaccines / National Research Council of Canada/ Therapure Biomanufacturing,Pre-clinical,Virus-like particle,Canada,CAN,3/14/2021,"Phase I/II trial of VBI-2902a expected to begin March 2021; Phase I trial of VBI-2905, targeting the B.1.351 variant, expected to begin mid-year 2021",Coalition for Epidemic Preparedness (CEPI)
"Verndari/ University of California, Davis",Pre-clinical,Protein subunit,United States,USA,8/27/2020,"Preliminary pre-clinical results are expected in the second half of 2020, Phase I trial is expected to begin thereafter; Selected by BARDA DRIVe for support in August 2020","Biomedical Advanced Research and Development Authority (BARDA) Division of Research, Innovation, and Ventures (DRIVe)"
"VIDO-InterVac, University of Saskatchewan",Phase I/II,Protein subunit,Canada,CAN,2/27/2021,Phase I/II dosed February 2021; Animal testing results expected in April 2020,The Government of Saskatchewan and the Canadian Federal Government
Vir Biotechnology / GSK,Pre-clinical,Unknown,United States,USA,Prior to 4/20/2020,Unknown,Unknown
Vivaldi Biosciences/ Esco Aster Pte Ltd,Pre-clinical,Unknown,United States,USA,6/2/2020,Unknown,Unknown
Walter Reed Army Institute of Research (WRAIR) / U.S. Army Medical Research and Development Command,Phase I,Protein subunit,United States,USA,6/30/2021,Phase I began recruiting April 2021,Unknown
"West China Hospital, Sichuan University",Phase II,Protein subunit,China,CHN,2/4/2021,Phase II began November 2020; Phase I began end of August 2020; Animal study data published July 2020,Unknown
Wuhan Institute of Biological Products/ Sinopharm,Phase III,Inactivated virus,China,CHN,3/22/2021,"China granted ""conditional approval"" on 2/25/2021; Applied for regulatory approval in China as of February 2021; Phase III trial began July 2020; Phase I/II early trial results released June 2020, Phase I/II interim analysis published August 2020; Received early approval for ""emergency use"" in China (Aug 2020) and the UAE (Sep 2020)",Unknown
Yisheng Biopharma,Pre-clinical,Protein subunit,China,CHN,6/30/2021,Clinical trials expected to begin Q2 2021,Unknown
Ziphius Therapeutics/ Ghent University,Pre-clinical,RNA-based vaccine,Belgium,BEL,4/28/2020,Unknown,Unknown
Zydus Cadila Healthcare Limited,Phase III,DNA-based,India,IND,7/29/2021,"Applied to the office of Drug Controller General of India (DCGI) for EUA on 7/1/2021; Phase III data expected to be announced May 2021; Phase III dosed January 2021; Pre-clinical results released January 2021; DCGI approved start of Phase III trial in January 2021; Phase I/II study: Phase I began July 2020 and Phase II began August 2020, initial results expected September 2020",Unknown
Zydus Cadila Healthcare Limited,Pre-clinical,Replicating viral vector,India,IND,7/8/2020,Unknown,Unknown